The Not-So-Good : They arent always the most effective for treating established GLP-1 constipation but can be helpful in preventing it or for mild cases of difficulty passing stool on GLP-1
To qualify, you must be 18, have Medicare Part D (prescription drug coverage) and meet the programs clinical criteria: A BMI of 35 or higher A BMI of 30 or higher and one or more of the following conditions: a diagnosis of heart failure with preserved ejection fraction, uncontrolled hypertension while on at least two blood pressure medications, or chronic kidney disease stage 3a or above A BMI of 27 or higher and one or more of the following conditions a diagnosis of pre-diabetes, a previous heart attack or stroke, or symptomatic peripheral artery disease Those with type 2 diabetes, moderate to severe obstructive sleep apnea, or MASH (fatty liver disease) are ineligible for the Medicare GLP-1 Bridge program
Crosstalk between incretin hormones, Th17 and Treg cells in inflammatory diseases
Conclusion Over the past years, GLP-1 antagonists have become a game-changer in weight management, offering a powerful tool for those struggling with obesity or Type 2 diabetes
Microdosing typically refers to taking subtherapeutic doses (smaller doses than the usual recommendations) of a drug to achieve benefits while minimizing side effects
Space alcoholic beverages several hours apart from doses, eat a balanced meal before drinking, and stay hydrated with water throughout the day